B Group Inc. Purchases New Shares in ADMA Biologics, Inc. (NASDAQ:ADMA)

B Group Inc. bought a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,287,542 shares of the biotechnology company's stock, valued at approximately $39,231,000. ADMA Biologics comprises 24.0% of B Group Inc.'s portfolio, making the stock its 2nd largest position. B Group Inc. owned about 0.97% of ADMA Biologics at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. GAMMA Investing LLC raised its position in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 967 shares during the last quarter. Mark Sheptoff Financial Planning LLC bought a new stake in shares of ADMA Biologics during the 4th quarter valued at about $35,000. Vision Financial Markets LLC acquired a new stake in ADMA Biologics during the fourth quarter worth approximately $51,000. AlphaQuest LLC bought a new stake in ADMA Biologics in the fourth quarter worth approximately $84,000. Finally, CIBC Private Wealth Group LLC boosted its holdings in shares of ADMA Biologics by 137.1% during the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock worth $95,000 after buying an additional 2,954 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Stock Up 2.8 %

ADMA stock traded up $0.60 during midday trading on Thursday, reaching $22.33. 2,169,905 shares of the company's stock traded hands, compared to its average volume of 3,632,194. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm's fifty day moving average price is $18.55 and its 200-day moving average price is $18.26. ADMA Biologics, Inc. has a 52 week low of $6.26 and a 52 week high of $23.64. The company has a market cap of $5.28 billion, a price-to-earnings ratio of 79.75 and a beta of 0.53.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.